MedPlus Subsidiary Drug License Suspensions Rise to 22 Stores

MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received an additional suspension order for a drug license at a store in Karnataka. This follows previous regulatory actions reported in Maharashtra, Telangana, Karnataka, Delhi, and Andhra Pradesh. The regulatory actions now span twenty-two separate stores across six states, each involving a suspension of the drug license under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The disclosures were made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Drug License Suspension Details

The following table summarises the key details of all regulatory actions as disclosed by the company:

Parameter:	Store 1	Store 2	Store 3	Store 4	Store 5	Store 6	Store 7	Store 8	Store 9	Store 10	Store 11	Store 12	Store 13	Store 14	Store 15	Store 16	Store 17	Store 18	Store 19	Store 20	Store 21	Store 22
Authority:	Asst. Commissioner & Licensing Authority, FDA, MH, Nashik	Assistant Director, DCA, Nizamabad, Telangana	Assistant Director, DCA, Bidar Circle, Karnataka	Assistant Director, DCA, F-17, Karkardooma, Delhi	Assistant Director, DCA, Bangalore circle-2, Karnataka	Assistant Director, DCA, Chikkamagalur Circle, Karnataka	Assistant Director, DCA, Hospet Circle, Vijaynagar, Karnataka	Assistant Director, Drugs Control Administration, Shameerpet, Telangana	Assistant Director, Drugs Control Administration, Siddipet, Telangana	Assistant Director, Drugs Control Administration, Shimoga Circle, Karnataka	Assistant Director, Drugs Control Administration, Madikeri Circle, Karnataka	Assistant Director, Drugs Control Administration, Bangalore Circle-4, Karnataka	Assistant Director, Drugs Control Administration, Shameerpet-Mechel-Malkajgiri Dist, Telangana	Assistant Director, Drugs Control Administration Bangalore Rural Circle, Devanahalli, Karnataka	Assistant Director, Drugs Control Administration Bangalore circle-5, Bangalore, Karnataka	Assistant Director, Drugs Control Administration, Nalgonda, Telangana	Assistant Director, Drugs Control Administration, Serilingampali, Telangana	Assistant Director, Drugs Control Administration, Warangal, Telangana	Assistant Director, District sales licensing Authority, Drugs control Administration, Ongole, Andhra Pradesh	Assistant Director, Drugs Control Administration, Bangalore Circle-5, Bangalore, Karnataka	Not specified	Not specified
Nature of Action:	Suspension for five days	Suspension for one day	Suspension for one day	Suspension for one day	Suspension for three days	Suspension for two days	Suspension for two days	Suspension for three days	Suspension for two days	Suspension for five days	Suspension for two days	Suspension for three days	Suspension for three days	Suspension for two days	Suspension for one day	Suspension for five days	Suspension for two days	Suspension for one day	Suspension for fifteen days	Suspension for two days	Not specified	Not specified
Store Location:	Samta Nagar, Nashik, Maharashtra	Metpally Road Armoor, Telangana	Shivnagar Bidar, Karnataka	Gopal Nagar, New Delhi	Kalidasa Layout, Karnataka	Mg Road Chikkamagaluru, Karnataka	Basaveshwara Nagar, Karnataka	Mallapur, Telangana	Market Road Narsapur, Telangana	Vinobha Nagar, Karnataka	Kohinoor Road, Madikeri, Karnataka	Nagarabhavi 2nd Stage, Karnataka	Maruthi Nagar Kothapet Village, Telangana	Channappa Layout Nelamangala, Karnataka	Binny Mill Road Ganganagar, Karnataka	Nareducharla Main Road, Telangana	Laxmi Nagar Colony Hydershahkote Exp, Telangana	Janagon Alladi complex, Telangana	Ongole Kurnool Road, Andhra Pradesh	Kacharakanahalli, Bangalore, Karnataka	Karnataka	Karnataka
Date of Receipt of Order:	May 06, 2026	May 08, 2026	Not specified	May 10, 2026	May 11, 2026	Not specified	May 12, 2026	May 15, 2026	May 20, 2026	Not specified	May 22, 2026	Not specified	May 27, 2026	Not specified	Not specified	May 30, 2026	Not specified	June 02, 2026	June 04, 2026	June 09, 2026	Not specified	Not specified
Violation:	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Not specified	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Not specified	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Not specified	Not specified
Potential Revenue Loss:	Rs 0.75 lacs	Rs 0.09 lacs	Rs 0.15 lacs	Rs 0.30 lacs	Rs 0.64 lacs	Rs 2.07 lacs	Rs 0.76 lacs	Rs 2.49 lacs	Rs 0.18 lacs	Rs 4.85 lacs	Rs 0.54 lacs	Rs 1.98 lacs	Rs 1.35 lacs	Rs 1.49 lacs	Rs 0.65 lacs	Rs 0.85 lacs	Rs 0.18 lacs	Rs 0.80 lacs	Rs 1.50 lacs	Rs 1.48 lacs	Not specified	Not specified

Regulatory and Financial Impact

The latest update includes a suspension for a store in Karnataka, bringing the cumulative count of affected stores to twenty-two. The total potential revenue loss across all reported suspensions where figures are available amounts to Rs 23.95 lacs.

The disclosures were made by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer of MedPlus Health Services. The details of these regulatory actions are available on the company's website at www.medplusindia.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.83%	-3.21%	-7.09%	+1.79%	-5.90%	-25.52%

MedPlus Health Services Limited announced the completion of the tenures of Mr. Madhavan Ganesan and Mr. Murali Sivaraman as Non-Executive Independent Directors on June 10, 2026. Both directors ceased to hold their positions at the end of business hours on June 10, 2026, following the conclusion of their first term with the company. The Board of Directors and management expressed their appreciation for the contributions made by the directors during their tenure.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation references a Master Circular dated January 30, 2026, regarding the details of the cessation. The company confirmed that the information is available on its website and the portals of BSE Limited and National Stock Exchange of India Limited.

Details of Cessation

The following table outlines the particulars regarding the change in directorship as per the regulatory filing:

Particulars	Mr. Madhavan Ganesan (DIN: 01674529)	Mr. Murali Sivaraman (DIN: 01461231)
Reason for Change	Completion of first tenure as an Independent Director of the Company.	Completion of first tenure as an Independent Director of the Company.
Date of Cessation	June 10, 2026 (Closing of Business hours)	June 10, 2026 (Closing of Business hours)
Brief Profile	NA	NA
Disclosure of relationships	NA	NA